ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018
Single-cell heterogeneity in ductal carcinoma in situ of breast.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.Cancer research communications · 2025Article
- Identification of unique rectal cancer-specific subtypes.British journal of cancer · 2024Article
- AZGP1 deficiency promotes angiogenesis in prostate cancer.Journal of translational medicine · 2024Article
- Applicability of Spatial Technology in Cancer Research.Cancer research and treatment · 2024Review
- Pathobiology of Candida auris infection analyzed by multiplexed imaging and single cell analysis.PloS one · 2024Article
- Article
- Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer.Nature communications · 2023Article
- Review
- Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting.International journal of molecular sciences · 2022Article
- The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.NPJ breast cancer · 2022Article
- Single-Cell Sequencing and Its Applications in Liver Cancer.Frontiers in oncology · 2022Review
- Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast.Nature communications · 2021Article
- Improving DCIS diagnosis and predictive outcome by applying artificial intelligence.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.Virchows Archiv : an international journal of pathology · 2021Article
- Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.Journal of hematology & oncology · 2021Review
- Genomic Alterations during theMolecular cancer research : MCR · 2021Article
- Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity.PloS one · 2021Article
- Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.BMC medical genomics · 2020Article
- Analysis of Spatial Distribution and Prognostic Value of Different Pan Cytokeratin Immunostaining Intensities in Breast Tumor Tissue Sections.International journal of molecular sciences · 2020Article
- Derivation of a nuclear heterogeneity image index to grade DCIS.Computational and structural biotechnology journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Heterogeneous patterns of mutations and RNA expression have been well documented in invasive cancers. However, technological challenges have limited the ability to study heterogeneity of protein expression. This is particularly true for pre-invasive lesions such as ductal carcinoma in situ of the breast. Cell-level heterogeneity in ductal carcinoma in situ was analyzed in a single 5 μm tissue section using a multiplexed immunofluorescence analysis of 11 disease-related markers (EGFR, HER2, HER4, S6, pmTOR, CD44v6, SLC7A5 and CD10, CD4, CD8 and CD20, plus pan-cytokeratin, pan-cadherin, DAPI, and Na+K+ATPase for cell segmentation). Expression was quantified at cell level using a single-cell segmentation algorithm. K-means clustering was used to determine co-expression patterns of epithelial cell markers and immune markers. We document for the first time the presence of epithelial cell heterogeneity within ducts, between ducts and between patients with ductal carcinoma in situ. There was moderate heterogeneity in a distribution of eight clusters within each duct (average Shannon index 0.76; range 0-1.61). Furthermore, within each patient, the average Shannon index across all ducts ranged from 0.33 to 1.02 (s.d. 0.09-0.38). As the distribution of clusters within ducts was uneven, the analysis of eight ducts might be sufficient to represent all the clusters ie within- and between-duct heterogeneity. The pattern of epithelial cell clustering was associated with the presence and type of immune infiltrates, indicating a complex interaction between the epithelial tumor and immune system for each patient. This analysis also provides the first evidence that simultaneous analysis of both the epithelial and immune/stromal components might be necessary to understand the complex milieu in ductal carcinoma in situ lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.